GetAntibody positions itself as a “no-code antibody design” workspace, aiming to let users design, evaluate, and optimize therapeutic antibodies directly in the browser. The public website emphasizes that it is an informational site, while the actual dynamic research workflows run inside the secure workspace at portal.getantibody.com. Access is currently invite-only.
Based on the crawled content, GetAntibody is not centered on a single model, but rather serves as a hub for antibody and protein AI tools. Its platform directory includes 124 tools, covering areas such as AlphaFold2, Boltz-2, Chai-1, Protenix, IntelliFold, RFdiffusion, RFantibody, DiffAb, Immune Builder, AntiFold, DiffDock-L, GNINA, ADMET-AI, and more. Its capabilities include sequence-to-structure prediction, antibody/nanobody/scFv/peptide design, epitope analysis, protein or small-molecule docking, affinity maturation, stability and developability checks, visualization of CDRs and binding interfaces, mutation effect analysis, and related workflows. Its main value is packaging processes that would otherwise require local deployment and switching between multiple tools into reusable, shareable team workflows.
The public materials do not disclose free quotas, trial duration, plan pricing, compute-based billing, or payment methods. They only state that users can get in touch to request invite access, collaboration review, or commercial discussions. As a result, it is difficult to assess cost-effectiveness at this stage. Access conditions from China are also not addressed in the main text; the connectivity of the domain and portal service, supported payment methods, and ease of compliant procurement all remain unknown.
Its strengths lie in relatively broad workflow coverage, making it suitable for structure-driven antibody discovery teams that need to quickly compare different models and design strategies. The interactive structure and sequence viewers are also useful for reviewing CDRs, paratopes, complexes, and residue-level interactions. The main limitation is its clear early-access nature: features and access policies may change, and the public information lacks key details such as model benchmarks, experimental validation, data retention, whether user data is used for training, enterprise-grade permissions, and audit capabilities. The terms also state that the content does not constitute medical, diagnostic, or regulatory advice, and that users must perform independent scientific validation.
GetAntibody is better suited to antibody engineering, computational biology, translational immunology, agricultural, or veterinary antibody R&D teams for early candidate generation, structural assessment, and workflow exploration. If you need transparent pricing, an open API, local deployment, or Chinese-language support, you may also want to evaluate alternatives such as Benchling, Schrödinger BioLuminate, or self-hosted stacks based on AlphaFold/ColabFold, Boltz, Chai-1, RFdiffusion, AutoDock Vina, and similar tools.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on getantibody.com official site.
getantibody.com is an United States AI Apps provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach getantibody.com directly.